TheSecond Cardiovascular InnovationsChina(CIC)Summitwill be held inNanjingin June
At China CardiovascularInnovations (CIC) press conference held in Beijing on March 19, 2015, Professor Kong Xiangqing, ExecutiveChairman of China Cardiovascular Innovations (CIC), President of the FirstClinical Medical College, Nanjing Medical University and Director ofCardiology, the First Affiliated Hospital of Nanjing Medical Universityintroduced: “The purpose of CICis to explore and establish an effective mechanism that can combine theclinical treatment concept and designs of product to the needs of patients inChina, which ultimately comes to a satisfying resolution for those in needs”, and The second CIC is organized by theChinese Society of Cardiology (CSC) and the Chinese Society of Pacing andElectrophysiology (CSPE), and hosted by the First Affiliated Hospital ofNanjing Medical University.
The press conference was chaired by ProfessorKong Xiangqing. CSC Chairman Professor Huo Yong from Peking University FirstHospital delivered a speech on the significance of translational medicine; CSPEChairman Professor Huang Congxin from Renmin Hospital of Wuhan University onthe national strategic value of medical innovation for China; Professor ZhangShu, former CSPE Chairman and Chairman of Chinese Academy Society ofArrhythmias, Chinese Medical Doctor Association on the role and function ofdoctors in medical innovation; Michael Zhao, Deputy Director of Jiangsu Provincial Cardiovascular Diagnostic Equipment EngineeringCenter of Jiangsu ProvincePeople's Hospital on the influence of China’s medical innovation on the world’spattern and its significance for national health; and ICI Chairman Professor Chaim Lotan(Israel) on the strategic partnership between CIC and ICI.
Translational medicine is an area of focalattention to drive a much closer partnership between the medical community andthe industry in order to streamline clinical concepts, engineering capabilitiesand investment dollars, all of which are indispensible for medical innovation.In 2013, CIC was launched by Chinese medical experts, and proposed theobjective to become the leader in the field ofChina’s “translational medicine”.As the exclusive partner of ICI, the InternationalConference for Innovations in Cardiovascular Systems and High-Tech Life ScienceIndustry inChina, CIC provides a close communication and exploration platform for clinical physicians in cardiovascular fields, public health policy makers and industry investors. Parties of eachfield can cooperatively research, develop and translate innovative treatment methods and products based on the needs and benefits of thepatients. For medical workers,CIC provides a very good platform and opportunity for some insightful Chinesedoctors, including participating in frontier scientific research, matchingclinical needs with engineering feasibility, cooperating with enterprises andinvestors to incubate new technologies, and looking for financing andindustrialization channels for their own research products. Meanwhile, medicalenterprises can obtain more innovative ideas and practical experience fromclinical doctors, and more perfectly combine products with demands through CICplatform; investors can find products and creativity with the highestinvestment value, find good projects for their capital, and findindustrialization and financing channels for their creativity. Moreimportantly, CIC aims to change the “imitation” mode ofChina’s national medical enterprises byincubating innovative medical devices with market value. The first CIC Summitwas already successfully held in January 2014. All participating expertsbelieve that the pragmatic CIC summit has provided a platform for medicalinnovation in the real sense, so that innovation can be carried out inpractice.
CIC Chairman Professor Huo Yong introducedthat the second CIC would carry forward the innovative mode of roundtablediscussion of previous sessions, and discuss 7 hot topics, namely percutaneousaortic valve replacement, percutaneous pulmonary valve replacement, mitral valverepair, tricuspidvalve repair, left atrialappendage, new treatmentof atrial fibrillation and pacemaker, and new coronary intervention. By then, theengineer representatives if many innovative medical enterprises and clinicalexperts of the innovative products to jointly demonstrate the points ofcombination between clinical needs and product design, and share theirexperience from creativity to clinical solutions. Besides, international topclinical experts will comment based on clinical needs and Chinese reality. CICChairman Professor Zhang Shu said: “We believe that casediscussion and brainstorming can greatly promote the feasibility from creativity toclinical solutions, tap investment value of projects, and build a platform wherehealthcare professionals, policy makers, industry representatives and investorscan come together to discuss and take collaborative actions to develop China’smuch needed new medical ideas, technologies and therapies to drive enhanced results.” CIC Executive Chairman Professor KongXiangqing said: “In the future, CIC hopes that clinical experts, public healthpolicy makers, the medical community and investors can closely cooperatethrough CIC in order to streamline clinical concepts, engineering capabilitiesand investment dollars. When ideas are given a stage, there will be infinitepossibilities in the future.”
As CIC’s Executive Chairman, Professor KongXiangqing himself is also a successfully practitioner of “translationalmedicine”. At the 2014 National Science and Technology Award Conference heldnot long ago, Professor Kong Xiangqing won the second prize of 2014 NationalTechnology Invention Award as the first inventor of “new equipment and newtechnology for interventional treatment of ventricular septal defect and theirclinical application techniques”, which was the only project of JiangsuProvince’s healthcare group to win such award.
